Center investigator and Associate Professor of Psychiatry, Stephan Sanders, BMBS, PhD, and colleagues have developed a catalogue of genetic variants that underlie prenatal, postnatal, and childhood development of the prefrontal cortex.
Administering stem cell or enzyme therapy in utero may be a path to alleviating some congenital diseases that often result in losing a pregnancy. In mouse studies, transplanted stem cells migrated to proper locations in fetal brain and body, differentiated into cells that produce crucial missing protein.
Our Co-Founder, Tippi MacKenzie, MD, was featured in an article in Time Magazine discussing the alpha thalassemia major (ATM) clinical trial: Scientists Are Developing New Ways to Treat Disease With Cells, Not Drugs
You can read the full article here.
The general goal of fetal therapy is to act early enough to minimize or even prevent lasting harm from severe problems that start in the womb. With a bone-marrow transplant, the added advantage of giving it before birth is that the fetal immune system is not yet fully developed, so it is unlikely to reject the transplant. Full article (New York Times).